Back to Freepaper Session
Management of corneal angiogenesis with the use of sub conjuctival injection of Bevacizumab 2.5mg/ 0.1ml
Session Title: Cornea Medical
Session Date/Time: Monday 07/10/2013 | 08:00-10:00
Paper Time: 08:50
Venue: Elicium 1 (First Floor)
First Author: : S.Nankani INDIA
Co Author(s): :
To determine the anti angiogenetic effect of sub conjuctival application of Bevacizumab for inhibition and treatment of Corneal angiogenesis ( both non established vascularisation and established vascularisation)
Krishna Eye Centre, Mumbai, India
30 eyes of 30 patients with Corneal angiogenesis were divided into 2 groups. Group A: Corneal Neovascularisation of single quadrant.
Group B: established vascularisation and neovascularisation of 2 or more quadrants. All eyes were injected with 2.5mg/0.1ml of Bevacizumab subconjuctivally, 2 mm away from the limbus. All patients were followed up for examination and photographed post injection at 1 week, 1 month, 3 months and 6 months.
All 30 eyes with neovascularisation showed regression of vasculature which was obvious at the end of 1 week and lasted for 3 months. Eyes with established vasculature failed to show any regression at the end of 1 week, 1 month or 3 months. at the end of 3 months, 8 eyes showed regrowth of vasculature and responded in respect to how many quadrants were involved to the injection
Data presented in this study demonstrates the effectiveness of subconjuctival application of Bevacizumab for inhibition and treatment of non established neovascularisation of the cornea, though 25% of the eyes required reinjection between 3 to 6 months